SCOTTSDALE, Ariz., Feb. 27, 2008 (PRIME NEWSWIRE) -- Medicis (NYSE:MRX) today announced revenues for the three months ended December 31, 2007 of approximately $140.3 million, compared to approximately $99.1 million for the three months ended December 31, 2006, representing an increase of approximately 42%. This increase was primarily due to strength in prescriptions of our core acne products, which include SOLODYN(R), TRIAZ(R) and ZIANA(R). Medicis' net income in accordance with U.S. generally accepted accounting principles ("GAAP") for the three months ended December 31, 2007 was approximately $27.5 million, or approximately $0.41 per diluted share, compared to net income in accordance with GAAP of $17.9 million, or approximately $0.27 per share, for the three months ended December 31, 2006. Non-GAAP net income for the three months ended December 31, 2007 was approximately $36.8 million, or approximately $0.54 per diluted share, compared to GAAP and non-GAAP net income of $17.9 million, or $0.27 per diluted share, for the three months ended December 31, 2006. There were no non-GAAP adjustments for the three months ended December 31, 2006.
